Compare SCLX & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | SRL |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 83.0M |
| IPO Year | N/A | N/A |
| Metric | SCLX | SRL |
|---|---|---|
| Price | $9.03 | $8.94 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.8K | 40.6K |
| Earning Date | 11-14-2025 | 04-24-2026 |
| Dividend Yield | N/A | ★ 11.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,360,000.00 | $26,224,099.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $749.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.60 | $5.13 |
| 52 Week High | $34.27 | $9.64 |
| Indicator | SCLX | SRL |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 56.73 |
| Support Level | $7.82 | $8.68 |
| Resistance Level | $10.41 | $9.15 |
| Average True Range (ATR) | 1.02 | 0.35 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 20.56 | 20.56 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.